SARS-CoV-2 BNT162b2 vaccine–induced humoral response and reactogenicity in individuals with prior COVID-19 disease

BACKGROUND: Most individuals with prior COVID-19 disease manifest long-term protective immune responses against reinfection. Accordingly, we tested the hypothesis that humoral immune and reactogenicity responses to a SARS-CoV-2 mRNA vaccine differ in individuals with and without prior COVID-19 disea...

Descripción completa

Detalles Bibliográficos
Autores principales: Kelsen, Steven G., Braverman, Alan S., Aksoy, Mark O., Hayman, Jacob A., Patel, Puja S., Rajput, Charu, Zhao, Huaqing, Fisher, Susan G., Ruggieri, Michael R., Gentile, Nina T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Clinical Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876462/
https://www.ncbi.nlm.nih.gov/pubmed/35019861
http://dx.doi.org/10.1172/jci.insight.155889

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876462/
https://www.ncbi.nlm.nih.gov/pubmed/35019861
http://dx.doi.org/10.1172/jci.insight.155889

Ejemplares similares